Literature DB >> 31243866

Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.

Johann Bauersachs1, Tobias König1, Peter van der Meer2, Mark C Petrie3, Denise Hilfiker-Kleiner1, Amam Mbakwem4, Righab Hamdan5, Alice M Jackson3, Paul Forsyth3, Rudolf A de Boer2, Christian Mueller6, Alexander R Lyon7, Lars H Lund8, Massimo F Piepoli9, Stephane Heymans10,11,12, Ovidiu Chioncel13, Stefan D Anker14, Piotr Ponikowski15, Petar M Seferovic16, Mark R Johnson17, Alexandre Mebazaa18, Karen Sliwa19.   

Abstract

Peripartum cardiomyopathy (PPCM) is a potentially life-threatening condition typically presenting as heart failure with reduced ejection fraction (HFrEF) in the last month of pregnancy or in the months following delivery in women without another known cause of heart failure. This updated position statement summarizes the knowledge about pathophysiological mechanisms, risk factors, clinical presentation, diagnosis and management of PPCM. As shortness of breath, fatigue and leg oedema are common in the peripartum period, a high index of suspicion is required to not miss the diagnosis. Measurement of natriuretic peptides, electrocardiography and echocardiography are recommended to promptly diagnose or exclude heart failure/PPCM. Important differential diagnoses include pulmonary embolism, myocardial infarction, hypertensive heart disease during pregnancy, and pre-existing heart disease. A genetic contribution is present in up to 20% of PPCM, in particular titin truncating variant. PPCM is associated with high morbidity and mortality, but also with a high probability of partial and often full recovery. Use of guideline-directed pharmacological therapy for HFrEF is recommended in all patients respecting contraindications during pregnancy/lactation. The oxidative stress-mediated cleavage of the hormone prolactin into a cardiotoxic fragment has been identified as a driver of PPCM pathophysiology. Pharmacological blockade of prolactin release using bromocriptine as a disease-specific therapy in addition to standard therapy for heart failure treatment has shown promising results in two clinical trials. Thresholds for devices (implantable cardioverter-defibrillators, cardiac resynchronization therapy and implanted long-term ventricular assist devices) are higher in PPCM than in other conditions because of the high rate of recovery. The important role of education and counselling around contraception and future pregnancies is emphasised.
© 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology.

Entities:  

Keywords:  Heart failure; Peripartum cardiomyopathy; Pregnancy

Mesh:

Year:  2019        PMID: 31243866     DOI: 10.1002/ejhf.1493

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  53 in total

Review 1.  Neglected cardiovascular diseases and their significance in the Global North.

Authors:  Charle André Viljoen; Julian Hoevelmann; Elani Muller; Karen Sliwa
Journal:  Herz       Date:  2021-01-27       Impact factor: 1.443

Review 2.  ECG and arrhythmias in peripartum cardiomyopathy.

Authors:  David Duncker; Tobias J Pfeffer; Johann Bauersachs; Christian Veltmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-03-31

3.  High prevalence of reduced fertility and use of assisted reproductive technology in a German cohort of patients with peripartum cardiomyopathy.

Authors:  Tobias J Pfeffer; Manuel List; Johann Bauersachs; Denise Hilfiker-Kleiner; Cordula Schippert; Bernd Auber; Melanie Ricke-Hoch; Valeska Abou-Moulig; Dominik Berliner
Journal:  Clin Res Cardiol       Date:  2022-05-13       Impact factor: 5.460

Review 4.  Update on Management of Cardiovascular Diseases in Women.

Authors:  Fabiana Lucà; Maurizio Giuseppe Abrignani; Iris Parrini; Stefania Angela Di Fusco; Simona Giubilato; Carmelo Massimiliano Rao; Laura Piccioni; Laura Cipolletta; Bruno Passaretti; Francesco Giallauria; Angelo Leone; Giuseppina Maura Francese; Carmine Riccio; Sandro Gelsomino; Furio Colivicchi; Michele Massimo Gulizia
Journal:  J Clin Med       Date:  2022-02-22       Impact factor: 4.241

Review 5.  Pregnancy and cardiovascular disease.

Authors:  Karishma P Ramlakhan; Mark R Johnson; Jolien W Roos-Hesselink
Journal:  Nat Rev Cardiol       Date:  2020-06-09       Impact factor: 32.419

6.  Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry.

Authors:  Karen Sliwa; Mark C Petrie; Peter van der Meer; Alexandre Mebazaa; Denise Hilfiker-Kleiner; Alice M Jackson; Aldo P Maggioni; Cecile Laroche; Vera Regitz-Zagrosek; Maria Schaufelberger; Luigi Tavazzi; Jolien W Roos-Hesselink; Petar Seferovic; Karin van Spaendonck-Zwarts; Amam Mbakwem; Michael Böhm; Frederic Mouquet; Burkert Pieske; Mark R Johnson; Righab Hamdan; Piotr Ponikowski; Dirk J Van Veldhuisen; John J V McMurray; Johann Bauersachs
Journal:  Eur Heart J       Date:  2020-10-14       Impact factor: 29.983

Review 7.  Peripartum cardiomyopathy.

Authors:  Nivedita Jha; Ajay Kumar Jha
Journal:  Heart Fail Rev       Date:  2021-01-13       Impact factor: 4.214

Review 8.  Cardiovascular adverse events in pregnancy: A global perspective.

Authors:  Susy Kotit; Magdi Yacoub
Journal:  Glob Cardiol Sci Pract       Date:  2021-04-30

Review 9.  Acute heart failure.

Authors:  Mattia Arrigo; Mariell Jessup; Wilfried Mullens; Nosheen Reza; Ajay M Shah; Karen Sliwa; Alexandre Mebazaa
Journal:  Nat Rev Dis Primers       Date:  2020-03-05       Impact factor: 52.329

Review 10.  Heat Shock Proteins: Potential Modulators and Candidate Biomarkers of Peripartum Cardiomyopathy.

Authors:  Graham Chakafana; Timothy F Spracklen; Stephen Kamuli; Tawanda Zininga; Addmore Shonhai; Ntobeko A B Ntusi; Karen Sliwa
Journal:  Front Cardiovasc Med       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.